Under the agreement, Agenus’ two biologics facilities in California will be transferred to Zydus for an upfront $75 million payment and $50 million in potential payments.
The goal of the teaming is to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients globally.
